Current and Emerging Modalities for Detection of Cardiotoxicity in cardio-oncology

References

• Jemal A , WardE, HaoY, ThunM . Trends in the leading causes of death in the United States, 1970–2002 . JAMA294 ( 10 ), 1255 – 1259 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Jemal A , WardE, ThunM . Declining death rates reflect progress against cancer . PLoS ONE5 ( 3 ), e9584 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Howlader N , RiesLA, MariottoAB, ReichmanME, RuhlJ, CroninKA . Improved estimates of cancer-specific survival rates from population-based data . J. Natl Cancer Inst.102 ( 20 ), 1584 – 1598 ( 2010 ).
   PubMedGoogle Scholar
• Siegel R , DesantisC, VirgoKet al. Cancer treatment and survivorship statistics, 2012 . CA Cancer J. Clin.62 ( 4 ), 220 – 241 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chapman JA , MengD, ShepherdLet al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer . J. Natl Cancer Inst.100 ( 4 ), 252 – 260 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hanrahan EO , Gonzalez-AnguloAM, GiordanoSHet al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma . J. Clin. Oncol.25 ( 31 ), 4952 – 4960 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM , LeipEP, LarsonMGet al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age . Circulation113 ( 6 ), 791 – 798 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Schairer C , MinkPJ, CarrollL, DevesaSS . Probabilities of death from breast cancer and other causes among female breast cancer patients . J. Natl Cancer Inst.96 ( 17 ), 1311 – 1321 ( 2004 ).
   PubMedGoogle Scholar
• Patnaik JL , ByersT, DiguiseppiC, DabeleaD, DenbergTD . Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study . Breast Cancer Res.13 ( 3 ), R64 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Colzani E , LiljegrenA, JohanssonALet al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics . J. Clin. Oncol.29 ( 30 ), 4014 – 4021 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jones LW , HaykowskyMJ, SwartzJJ, DouglasPS, MackeyJR . Early breast cancer therapy and cardiovascular injury . J. Am. Coll. Cardiol.50 ( 15 ), 1435 – 1441 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Yeh ET , BickfordCL . Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management . J. Am. Coll. Cardiol.53 ( 24 ), 2231 – 2247 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chu TF , RupnickMA, KerkelaRet al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib . Lancet370 ( 9604 ), 2011 – 2019 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hall PS , HarshmanLC, SrinivasS, WittelesRM . The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients . JACC Heart Fail1 ( 1 ), 72 – 78 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , LayardMW, BasaPet al. Risk factors for doxorubicin-induced congestive heart failure . Ann. Intern. Med.91 ( 5 ), 710 – 717 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Swain SM , WhaleyFS, EwerMS . Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials . Cancer97 ( 11 ), 2869 – 2879 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Perez EA , SumanVJ, DavidsonNEet al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial . J. Clin. Oncol.22 ( 18 ), 3700 – 3704 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Meinardi MT , Van VeldhuisenDJ, GietemaJAet al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients . J. Clin. Oncol.19 ( 10 ), 2746 – 2753 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Mackey JR , MartinM, PienkowskiTet al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10 year follow-up of the phase 3 randomised BCIRG 001 trial . Lancet Oncol.14 ( 1 ), 72 – 80 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wouters KA , KremerLC, MillerTL, HermanEH, LipshultzSE . Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies . Br. J. Haematol.131 ( 5 ), 561 – 578 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Schmidinger M , ZielinskiCC, VoglUMet al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma . J. Clin. Oncol.26 ( 32 ), 5204 – 5212 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Tocchetti CG , RagoneG, CoppolaCet al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge . Eur. J. Heart Fail.14 ( 2 ), 130 – 137 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Force T , KolajaKL . Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes . Nat. Rev. Drug Discov.10 ( 2 ), 111 – 126 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ky B , VejpongsaP, YehET, ForceT, MoslehiJJ . Emerging paradigms in cardiomyopathies associated with cancer therapies . Circ. Res.113 ( 6 ), 754 – 764 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E , YothersG, RomondEet al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 . J. Clin. Oncol.23 ( 31 ), 7811 – 7819 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Perez EA , RodehefferR . Clinical cardiac tolerability of trastuzumab . J. Clin. Oncol.22 ( 2 ), 322 – 329 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Cheng H , ForceT . Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics . Circ. Res.106 ( 1 ), 21 – 34 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Telli ML , HuntSA, CarlsonRW, GuardinoAE . Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility . J. Clin. Oncol.25 ( 23 ), 3525 – 3533 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events V4.03 (CTCAE) . http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf .
   Google Scholar
• Seidman A , HudisC, PierriMKet al. Cardiac dysfunction in the trastuzumab clinical trials experience . J. Clin. Oncol.20 ( 5 ), 1215 – 1221 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM, BozkurtBet al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . J. Am. Coll. Cardiol.62 ( 16 ), e147 – E239 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ammar KA , JacobsenSJ, MahoneyDWet al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community . Circulation115 ( 12 ), 1563 – 1570 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , ColomboA, LamantiaGet al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy . J. Am. Coll. Cardiol.55 ( 3 ), 213 – 220 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lenihan DJ , SawyerDB . Heart disease in cancer patients: a burgeoning field where optimizing patient care is requiring interdisciplinary collaborations . Heart Fail. Clin.7 ( 3 ), xxi – xxiii ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Plana JC , GalderisiM, BaracAet al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Standardizecardiography and the European Association of Cardiovascular Imaging . J. Am. Soc. Standardizecardiogr.27 ( 9 ), 911 – 939 ( 2014 ).
   Google Scholar
• Khouri MG , DouglasPS, MackeyJRet al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues . Circulation126 ( 23 ), 2749 – 2763 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Curigliano G , CardinaleD, SuterTet al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines . Ann. Oncol.23 ( Suppl. 7 ), vii155 – vii166 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Verma S , EwerMS . Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer . Ann. Oncol.22 ( 5 ), 1011 – 1018 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bellenger NG , BurgessMI, RaySGet al. Comparison of left ventricular ejection fraction and volumes in heart failure by standardizecardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable . Eur. Heart J.21 ( 16 ), 1387 – 1396 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ewer MS , LenihanDJ . Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground . J. Clin. Oncol.26 ( 8 ), 1201 – 1203 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Trastuzumab (Herceptin®) , package insert . Genentech, Inc., CA, USA .
   Google Scholar
• Romond EH , JeongJH, RastogiPet al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer . J. Clin. Oncol.30 ( 31 ), 3792 – 3799 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Romond EH , PerezEA, BryantJet al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N. Engl. J. Med.353 ( 16 ), 1673 – 1684 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Slamon D , EiermannW, RobertNet al. Adjuvant trastuzumab in HER2-positive breast cancer . N. Engl. J. Med.365 ( 14 ), 1273 – 1283 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Schmitz KH , ProsnitzRG, SchwartzAL, CarverJR . Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors . Cancer118 ( 8 Suppl. ), 2270 – 2276 ( 2012 ).
   PubMedGoogle Scholar
• Ewer MS , AliMK, MackayBet al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin . J. Clin. Oncol.2 ( 2 ), 112 – 117 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Delgado V , MollemaSA, YpenburgCet al. Relation between global left ventricular longitudinal strain assessed with novel automated function imaging and biplane left ventricular ejection fraction in patients with coronary artery disease . J. Am. Soc. Echocardiogr.21 ( 11 ), 1244 – 1250 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Mann DL , BristowMR . Mechanisms and models in heart failure: the biomechanical model and beyond . Circulation111 ( 21 ), 2837 – 2849 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Doyle JJ , NeugutAI, JacobsonJS, GrannVR, HershmanDL . Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study . J. Clin. Oncol.23 ( 34 ), 8597 – 8605 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Jones LW , EvesND, HaykowskyM, FreedlandSJ, MackeyJR . Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction . Lancet Oncol.10 ( 6 ), 598 – 605 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lakoski SG , EvesND, DouglasPS, JonesLW . Exercise rehabilitation in patients with cancer . Nat. Rev. Clin. Oncol.9 ( 5 ), 288 – 296 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chaosuwannakit N , D’agostinoRJr, HamiltonCAet al. Aortic stiffness increases upon receipt of anthracycline chemotherapy . J. Clin. Oncol.28 ( 1 ), 166 – 172 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Beckman JA , ThakoreA, KalinowskiBH, HarrisJR, CreagerMA . Radiation therapy impairs endothelium-dependent vasodilation in humans . J. Am. Coll. Cardiol.37 ( 3 ), 761 – 765 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Koelwyn GJ , KhouriM, MackeyJR, DouglasPS, JonesLW . Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship . J. Clin. Oncol.30 ( 36 ), 4458 – 4461 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Walker J , BhullarN, Fallah-RadNet al. Role of three-dimensional standardizecardiography in breast cancer: comparison with two-dimensional standardizecardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging . J. Clin. Oncol.28 ( 21 ), 3429 – 3436 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P , GrantAD, NegishiT, PlanaJC, PopovicZB, MarwickTH . Reproducibility of standardizecardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy . J. Am. Coll. Cardiol.61 ( 1 ), 77 – 84 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cranney GB , LotanCS, DeanL, BaxleyW, BouchardA, PohostGM . Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography . Circulation82 ( 1 ), 154 – 163 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Grothues F , SmithGC, MoonJCet al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional standardizecardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy . Am. J. Cardiol.90 ( 1 ), 29 – 34 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Sandner TA , HouckP, RungeVMet al. Accuracy of accelerated cine MR imaging at 3 Tesla in longitudinal follow-up of cardiac function . Eur. Radiol.18 ( 10 ), 2095 – 2101 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Mcmurray JJ , AdamopoulosS, AnkerSDet al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC . Eur. Heart J.33 ( 14 ), 1787 – 1847 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kalam K , OtahalP, MarwickTH . Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction . Heart100 ( 21 ), 1673 – 1680 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Watts RG , GeorgeM, JohnsonWHJr . Pretreatment and routine standardizecardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center . Cancer118 ( 7 ), 1919 – 1924 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Carver JR , ShapiroCL, NgAet al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects . J. Clin. Oncol.25 ( 25 ), 3991 – 4008 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Gorcsan J 3rd , TanakaH . Standardizecardiographic assessment of myocardial strain . J. Am. Coll. Cardiol.58 ( 14 ), 1401 – 1413 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sengupta PP , TajikAJ, ChandrasekaranK, KhandheriaBK . Twist mechanics of the left ventricle: principles and application . JACC Cardiovasc. Imaging1 ( 3 ), 366 – 376 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P , PoulinF, LimKD, PlanaJC, WooA, MarwickTH . Use of myocardial strain imaging by standardizecardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review . J. Am. Coll. Cardiol.63 ( 25 Pt A ), 2751 – 2768 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ganame J , ClausP, UyttebroeckAet al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients . J. Am. Soc. Echocardiogr.20 ( 12 ), 1351 – 1358 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Jurcut R , WildiersH, GanameJet al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer . J. Am. Soc. Echocardiogr.21 ( 12 ), 1283 – 1289 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hare JL , BrownJK, LeanoR, JenkinsC, WoodwardN, MarwickTH . Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab . Am. Heart J.158 ( 2 ), 294 – 301 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Mercuro G , CadedduC, PirasAet al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler standardizecardiography: correlation with inflammatory and oxidative stress markers . Oncologist12 ( 9 ), 1124 – 1133 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Sawaya H , SebagIA, PlanaJCet al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients . Am. J. Cardiol.107 ( 9 ), 1375 – 1380 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sawaya H , SebagIA, PlanaJCet al. Assessment of standardizecardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab . Circ. Cardiovasc. Imaging5 ( 5 ), 596 – 603 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Negishi K , NegishiT, HareJL, HaluskaBA, PlanaJC, MarwickTH . Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity . J. Am. Soc. Echocardiogr.26 ( 5 ), 493 – 498 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Motoki H , KoyamaJ, NakazawaHet al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy . Eur. Heart J. Cardiovasc. Imaging13 ( 1 ), 95 – 103 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cheung YF , LiSN, ChanGC, WongSJ, HaSY . Left ventricular twisting and untwisting motion in childhood cancer survivors . Echocardiography28 ( 7 ), 738 – 745 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Yu HK , YuW, CheukDK, WongSJ, ChanGC, CheungYF . New three-dimensional speckle-tracking echocardiography identifies global impairment of left ventricular mechanics with a high sensitivity in childhood cancer survivors . J. Am. Soc. Echocardiogr.26 ( 8 ), 846 – 852 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Risum N , AliS, OlsenNTet al. Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults . J. Am. Soc. Echocardiogr.25 ( 11 ), 1195 – 1203 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wassmuth R , LentzschS, ErdbrueggerUet al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study . Am. Heart J.141 ( 6 ), 1007 – 1013 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Isner JM , FerransVJ, CohenSRet al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy . Am. J. Cardiol.51 ( 7 ), 1167 – 1174 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Wadhwa D , Fallah-RadN, GrenierDet al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study . Breast Cancer Res. Treat.117 ( 2 ), 357 – 364 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Fallah-Rad N , WalkerJR, WassefAet al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy . J. Am. Coll. Cardiol.57 ( 22 ), 2263 – 2270 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Fallah-Rad N , LytwynM, FangT, KirkpatrickI, JassalDS . Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy . J. Cardiovasc. Magn. Reson.10, 5 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Neilan TG , Coelho-FilhoOR, Pena-HerreraDet al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines . Am. J. Cardiol.110 ( 11 ), 1679 – 1686 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Drafts BC , TwomleyKM, D’agostinoRJret al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease . JACC Cardiovasc. Imaging6 ( 8 ), 877 – 885 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Neilan TG , Coelho-FilhoOR, ShahRVet al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy . Am. J. Cardiol.111 ( 5 ), 717 – 722 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tham EB , HaykowskyMJ, ChowKet al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling . J. Cardiovasc. Magn. Reson.15, 48 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Estorch M , CarrioI, BernaLet al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer . J. Nucl. Med.31 ( 12 ), 1965 – 1969 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Carrio I , Lopez-PousaA, EstorchMet al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies . J. Nucl. Med.34 ( 9 ), 1503 – 1507 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Carrio I , EstorchM, BernaL, Lopez-PousaJ, TaberneroJ, TorresG . Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity . J. Nucl. Med.36 ( 11 ), 2044 – 2049 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Valdes Olmos RA , CarrioI, HoefnagelCAet al. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction . Nucl. Med. Commun.23 ( 9 ), 871 – 877 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Olmos RA , Ten Bokkel HuininkWW, Ten HoeveRFet al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy . Eur. J. Cancer31A ( 1 ), 26 – 31 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Lakoski SG , BarlowCE, KoelwynGJet al. The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study . Breast Cancer Res. Treat.138 ( 3 ), 909 – 916 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Khouri MG , HornsbyWE, RisumNet al. Utility of 3-dimensional standardizecardiography, global longitudinal strain, and exercise stress standardizecardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy . Breast Cancer Res. Treat.143 ( 3 ), 531 – 539 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mckillop JH , BristowMR, GorisML, BillinghamME, BockemuehlK . Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity . Am. Heart J.106 ( 5 Pt 1 ), 1048 – 1056 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Civelli M , CardinaleD, MartinoniAet al. Early reduction in left ventricular contractile reserve detected by dobutamine stress standardize predicts high-dose chemotherapy-induced cardiac toxicity . Int. J. Cardiol.111 ( 1 ), 120 – 126 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Smibert E , CarlinJB, VidmarS, WilkinsonLC, NewtonM, WeintraubRG . Exercise standardizecardiography reflects cumulative anthracycline exposure during childhood . Pediatr. Blood Cancer42 ( 7 ), 556 – 562 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• De Souza AM , PottsJE, PottsMTet al. A stress standardizecardiography study of cardiac function during progressive exercise in pediatric oncology patients treated with anthracyclines . Pediatr. Blood Cancer49 ( 1 ), 56 – 64 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Guimaraes-Filho FV , TanDM, BragaJC, RodriguesA, WaibPH, MatsubaraBB . Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines: a longitudinal, prospective exercise standardizecardiography study . Pediatr. Blood Cancer59 ( 3 ), 548 – 552 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sieswerda E , KremerLC, VidmarSet al. Exercise standardizecardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study . Pediatr. Blood Cancer54 ( 4 ), 579 – 584 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Klewer SE , GoldbergSJ, DonnersteinRL, BergRA, HutterJJJr . Dobutamine stress standardizecardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer . J. Am. Coll. Cardiol.19 ( 2 ), 394 – 401 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Lanzarini L , BossiG, LaudisaML, KlersyC, AricoM . Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines . Am. Heart J.140 ( 2 ), 315 – 323 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Gupta S , RohatgiA, AyersCRet al. Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality . Circulation123 ( 13 ), 1377 – 1383 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Gulati M , PandeyDK, ArnsdorfMFet al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project . Circulation108 ( 13 ), 1554 – 1559 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Jones LW , WatsonD, HerndonJE2ndet al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer . Cancer116 ( 20 ), 4825 – 4832 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Jones LW , HornsbyWE, GoetzingerAet al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer . Lung Cancer76 ( 2 ), 248 – 252 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Jones LW , CourneyaKS, MackeyJRet al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum . J. Clin. Oncol.30 ( 20 ), 2530 – 2537 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , SandriMT . Role of biomarkers in chemotherapy-induced cardiotoxicity . Prog. Cardiovasc. Dis.53 ( 2 ), 121 – 129 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Thigpen SC , GeraciSA . Prediction of anthracycline-induced left ventricular dysfunction by cardiac troponins . South. Med. J.105 ( 12 ), 659 – 664 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , SandriMT, MartinoniAet al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy . J. Am. Coll. Cardiol.36 ( 2 ), 517 – 522 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , SandriMT, ColomboAet al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy . Circulation109 ( 22 ), 2749 – 2754 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , SandriMT, MartinoniAet al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy . Ann. Oncol.13 ( 5 ), 710 – 715 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Sandri MT , CardinaleD, ZorzinoLet al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy . Clin. Chem.49 ( 2 ), 248 – 252 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , ColomboA, TorrisiRet al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation . J. Clin. Oncol.28 ( 25 ), 3910 – 3916 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Morris PG , ChenC, SteingartRet al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib . Clin. Cancer Res.17 ( 10 ), 3490 – 3499 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ky B , PuttM, SawayaHet al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab . J. Am. Coll. Cardiol.63 ( 8 ), 809 – 816 ( 2014 ).
   PubMed Web of Science ®Google Scholar